Ixazomib

Ixazomib functions as a reversible proteasome inhibitor due to its structure as a modified peptide boronic acid containing a single chiral center, classifying it as a boronate proteasome inhibitor.

The compound primarily consists of the R-enantiomer. The FDA sanctioned Ixazomib on November 20, 2015, marking its distinction as the first oral proteasome inhibitor endorsed in the United States. Following this, Health Canada approved it on August 3, 2016, and the European Medicines Agency (EMA) approved it on November 21, 2016.

Its applications extend beyond multiple myeloma, encompassing hematological malignancies and conditions such as AL amyloidosis, graft-versus-host disease, and lupus nephritis. Ixazomib is recommended explicitly in conjunction with lenalidomide and dexamethasone for treating patients with multiple myeloma who have undergone one prior therapy.